Topical imiquimod cream 5% for resistant perianal warts in a renal transplant patient

2002 ◽  
Vol 13 (7) ◽  
pp. 501-503 ◽  
Author(s):  
S L Gayed
Keyword(s):  
Renal Transplant ◽  
Effective Treatment ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Genital Warts ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Imiquimod Cream ◽  
Patient Subgroup ◽  
Genitourinary Medicine

Renal transplant recipients represent a patient subgroup for whom the effective treatment of genital warts poses a significant problem in genitourinary medicine. This case demonstrates the safe and effective treatment of resistant perianal warts in a male renal transplant recipient using imiquimod.

Topical imiquimod cream 5% for resistant perianal warts in a renal transplant patient

2002 ◽  
Vol 13 (5) ◽  
pp. 349-351 ◽  
Author(s):  
S L Gayed
Keyword(s):  
Renal Transplant ◽  
Effective Treatment ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Genital Warts ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Imiquimod Cream ◽  
Patient Subgroup ◽  
Genitourinary Medicine

Renal transplant recipients represent a patient subgroup for whom the effective treatment of genital warts poses a significant problem in genitourinary medicine. This case demonstrates the safe and effective treatment of resistant perianal warts in a male renal transplant recipient using imiquimod.

scholarly journals Fecal microbiota transplantation as an effective treatment for carbapenem-resistant Klebsiella pneumoniae infection in a renal transplant patient

2020 ◽  
Author(s):  
Junpeng Wang ◽  
Xin Li ◽  
Xiaoqiang Wu ◽  
Zhiwei Wang ◽  
Xuan Wu ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Renal Transplant ◽  
Klebsiella Pneumoniae ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Carbapenem Resistant

Abstract Background: In renal transplant recipients, carbapenem-resistant Klebsiella pneumoniae (CRKP) infection is common, and usually associated with severe clinical outcomes due to a lack of effective therapeutics.Case presentation: A 37-year-old female had a CRKP infection one month after the kidney transplantation. Since the effect of the antibiotic therapy was limited, fecal microbiota transplantation (FMT) was performed. FMT resulted in increased richness and diversity of gut microbiota and reduced relative abundance of Klebsiella. After FMT, the infection of the patient caused by CRKP was well controlled without inducing adverse effects.Conclusion: This study demonstrated the therapeutic effect of FMT on CRKP infection, and may shine some light on the treatment of the infections caused by CRKP for the patients after transplantation.

scholarly journals Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients

1998 ◽  
Vol 44 (9) ◽  
pp. 1942-1946 ◽  
Author(s):  
Jan L Cogill ◽  
Paul J Taylor ◽  
Ian S Westley ◽  
Raymond G Morris ◽  
Stephen V Lynch ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Therapeutic Drug ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Significant Difference ◽  
Microparticle Enzyme Immunoassay ◽  
Clinically Significant ◽  
Comparison Data

Abstract We evaluated the MEIA II with blood samples with added tacrolimus (3.0, 5.0, 11.0, and 22.0 μg/L). The assay had acceptable recoveries (99–103%) and intraday imprecision (<16.0%) across the range of concentrations studied, except for the recoveries at 3.0 μg/L (86.3%) and 5.0 μg/L (80.7%). Comparison of liver (n = 116) and renal (n = 113) patient samples measured by MEIA II against HPLC-tandem mass spectrometry (HPLC-MS/MS) found a mean overestimation of 15.6%. From these comparison data it can be calculated that at values of 5 and 20 μg/L in liver or renal transplant patient samples, measured by HPLC-MS/MS, MEIA II will have the corresponding range estimates of 3.6–7.9 μg/L and 20.9–25.4 μg/L, respectively. No clinically significant difference in results, in terms of overestimation or correlation, was observed between the two transplant groups studied. The MEIA II is an improvement on the previous MEIA I and is suitable for the therapeutic drug monitoring of tacrolimus where HPLC-MS/MS is unavailable.

scholarly journals IVIG Associated Aseptic Meningitis in a Renal Transplant Patient

2017 ◽  
Vol 2017 ◽  
pp. 1-3
Author(s):  
Tamara Wanigasekera ◽  
Rachel J. Grainger ◽  
Donal J. Sexton ◽  
Colm Magee
Keyword(s):  
Adverse Effect ◽  
Renal Transplant ◽  
Aseptic Meningitis ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Ivig Therapy ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Antibody Mediated Rejection

The management of antibody-mediated rejection in renal transplant recipients involves plasmapheresis with IVIG. Aseptic meningitis is a rare adverse effect of IVIG therapy and is a diagnosis of exclusion. We report a case of a renal transplant patient who developed IVIG associated aseptic meningitis in the context of management of antibody-mediated rejection, four years after transplantation.

scholarly journals COVID-19 in Renal Transplant Patient Presenting With Active Typical Symptoms and Resolved Atypical Symptoms

2020 ◽  
Vol 8 ◽  
pp. 232470962094930 ◽  
Author(s):  
Sreedhar Adapa ◽  
Venu Madhav Konala ◽  
Srikanth Naramala ◽  
Subba Rao Daggubati ◽  
Narayana Murty Koduri ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Gastrointestinal Symptoms ◽  
Published Data ◽  
The Novel ◽  
Transplant Recipients ◽  
Atypical Symptoms ◽  
Rapid Transmission ◽  
Novel Coronavirus

The novel coronavirus disease has brought the world to standstill with high infectivity and rapid transmission. The disease caused by novel coronavirus is termed as coronavirus disease 2019 (COVID-19). We present the case of a renal transplant patient who was infected with COVID-19 through community spread and presented with fever and gastrointestinal symptoms. Transplant recipients are particularly vulnerable because of the immunosuppressed state. These patients can shed a virus for a prolonged period and can have a higher load of the virus. There have been no COVID-19 cases transmitted through organ donation. Preinfection immunological impairment can aggravate the severity of the infection. The transplant team plays a crucial role in donor and recipient evaluation and guiding the timing of the transplant. Although specific published data are lacking with regard to transplant recipients, they should follow the same precautions as the general population, like avoiding nonessential travel and practice social distancing.

Diagnosis of Polyoma Virus Infection In Renal Transplant Recipients

1999 ◽  
Vol 5 (S2) ◽  
pp. 1166-1167
Author(s):  
J. A. C. King ◽  
D. N. Howell ◽  
J. A. Tucker ◽  
R. P. Lowry
Keyword(s):  
Renal Transplant ◽  
Virus Infection ◽  
Renal Transplant Patient ◽  
Bk Virus ◽  
Polyoma Virus ◽  
Immunosuppressed Patient ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Immunosuppressed Patients ◽  
Cadaver Kidney

BK polyoma virus is a 40-45 nm DNA virus that was first identified in the urine of an immunosuppressed patient in 1971. BK virus infection often occurs in childhood and is subclinical. The majority of adults have antibodies to the virus. Asymptomatic viruria, ureteral ulceration, and ureteral stenosis have been described with infection in immunosuppressed patients. Renal graft dysfunction and interstitial nephritis have been associated with BK virus. Differentiation between rejection and infection is important. We report a case of a renal transplant patient with BK polyoma virus infection. This case illustrates the variety of methods that can be used for identification of BK polyoma virus.The patient, a 52 year old female, presented with an asymptomatic rise in serum creatinine (1.4 to 2.1 mg/dl). Her past medical history was significant for a cadaver kidney transplant two years prior for polycystic kidney disease.

A Case of Cutaneous Mycobacterium Chelonae Abscessus Infection in a Renal Transplant Patient

2001 ◽  
Vol 5 (1) ◽  
pp. 28-32 ◽  
Author(s):  
Carin H. Endzweig ◽  
Eric Strauss ◽  
Frank Murphy ◽  
Babar K. Rao
Keyword(s):  
Renal Transplant ◽  
Skin Biopsy ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Treatment Options ◽  
Human Infection ◽  
High Rate ◽  
Renal Transplant Recipients ◽  
Mycobacterium Chelonae ◽  
Subcutaneous Nodules

Background: Mycobacterium chelonae is an atypical “fast-growing Mycobacteria” that is a rare cause of human infection. There have been several reports of cutaneous infection among immunosuppressed patients, as well as in immunocompetent individuals following trauma. Most cases to date seem to have occurred among renal transplant recipients, raising the possibility that there is something inherent to the renal transplant patient that increases their susceptibility more than other immunocompromised patients. Objective: The differential diagnosis of subcutaneous nodules distributed in a sporotri-choid pattern is extensive, particularly in an immunocompromised host. Although several cases of cutaneous M. chelonae abscessus infection have been reported among both immunosuppressed and immunocompetent patients, the clinical presentation has varied, and few cases have reported the appearance of lesions in a sporotrichoid pattern. We present a case of a renal transplant patient with a reported history of trauma to the lower extremities, who presents with subcutaneous nodules distributed in a sporotrichoid pattern. The patient is found to have M. chelonae abscessus infection, fails several treatment regimens, and presents with a recurrence. The literature of M. chelonae infection is reviewed, and the various treatment options are discussed. Methods: An initial skin biopsy was stained with Hematoxylin and Eosin and revealed deep dermal abscesses with acid-fast bacilli in clusters. The culture became positive for Mycobacterium chelonae abscesses in four days and was found to be sensitive to multiple antibiotics. The patient underwent surgical excision of 14 nodules, which revealed findings consistent with the skin biopsy, and was subsequently treated with the appropriate antibiotics. Results: Despite treatment with a full course of an organism-sensitive antibiotic regimen, the patient returned with persistent and recurrent nodules six weeks later. The patient was then treated as an inpatient with a seven-week course of intravenous antibiotics and was discharged home on a combined intravenous and oral regimen. Conclusion: Although M. chelonae abscessus is an extremely rare cause of infection among humans, there seems to be a predominance of cases reported among renal transplant patients. The explanation for this is not entirely clear; however, the organism must be considered as a cause of infection in any renal transplant recipient who presents with subcutaneous nodules. Eradication of the organism presents a tremendous challenge to the clinician, and, as presented here, even with appropriate antibiotics, there is a high rate of recurrence.

scholarly journals Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients

2005 ◽  
Vol 141 (8) ◽  
Author(s):  
Victoria L. Brown ◽  
Catherine L. Atkins ◽  
Lucy Ghali ◽  
Rino Cerio ◽  
Catherine A. Harwood ◽  
...  
Keyword(s):  
High Risk ◽  
Renal Transplant ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Imiquimod Cream ◽  
Safety And Efficacy

scholarly journals The use of convalescent plasma, dexamethasone and remdesivir in a renal transplant patient infected with COVID-19

2020 ◽  
Vol 8 (36) ◽  
pp. 81-85
Author(s):  
Sheena Hannabas ◽  
Gregory Hannabas ◽  
Camilo Pena
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplant ◽  
Renal Transplant Patient ◽  
Renal Allograft ◽  
Transplant Patient ◽  
Supplemental Oxygen ◽  
High Risk Population ◽  
Renal Transplant Recipients ◽  
West Texas ◽  
Allograft Function

Background Immunocompromised patients, such as renal transplant recipients, are a high-risk population for coronavirus disease 2019 (COVID-19) infection and complications. The evidence to support specific treatment of COVID-19 in this group of patients remains very limited. We present the first case in West Texas of a renal transplant patient who received combined therapy with convalescent plasma, dexamethasone, and remdesivir for the treatment of COVID-19. Case summary We report a female patient who received a deceased donor kidney transplant approximately 2 years prior. She was admitted to our institution with respiratory distress with symptomatic COVID-19 infection. Her baseline renal allograft function per serum creatinine was 0.9 mg/dL, and she was on maintenance immunosuppression with tacrolimus, mycophenolate mofetil, and prednisone. Throughout her hospitalization, her mycophenolate mofetil was maintained, the prednisone was switched for dexamethasone, and her tacrolimus dosage required multiple adjustments secondary to interactions with the azithromycin used to treat an atypical pneumonia upon admission to the hospital. The patient eventually required supplemental oxygen with a venti-mask at 50% FiO2 and transfer to the medical intensive care unit. She received convalescent plasma from a COVID-19 recovered patient, in addition to dexamethasone and then remdesivir for 5 days, with clinical improvement. She was discharged on 3 L per minute supplemental oxygen by nasal cannula from the hospital on day 17 of hospitalization. Conclusion This renal transplant patient in West Texas with symptomatic COVID-19 infection was treated with convalescent plasma, remdesivir, and dexamethasone with a good outcome. This case also shows the common and often missed drug interactions between tacrolimus and azithromycin and describes a safe way of lowering immunosuppression without compromising renal allograft function. Keywords: COVID-19, coronavirus, renal transplant, immunosuppression, convalescent plasma, dexamethasone, remdesivir, tacrolimus, mycophenolate mofetil.

Sign in / Sign up

Export Citation Format

Share Document